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Background: Artemisinin-based combination therapy (ACT) is the treatment of choice for uncomplicated
Plasmodium falciparum malaria in most areas of the world, where malaria is endemic, including Sudan. However,
few published data are available on the use of ACT for treatment of P. vivax malaria.
Methods: This study was conducted at a health centre in Kassala, eastern Sudan, from October to December 2011.
Patients with uncomplicated P. vivax malaria received artemether-lumefantrine (AL) tablets (containing 20mg
artemether and 120 mg lumefantrine) and were monitored for 28 days.
Results: Out of the 43 cases enrolled in this study, 38 completed the 28-day follow-up. Their mean age was 25.1
years (SD: 1.5). On day 3 following AL treatment, all of the patients were afebrile and aparasitaemic. By day 28, all
38 patients exhibited adequate clinical and parasitological responses to AL treatment. The cure rate was 100%
and 88.4% for the per protocol analysis andfor the intention to treat analysis, respectively. Mild adverse effects
(nausea, vomiting, abdominal pain, dizziness and/or rash) that resolved spontaneously were observed in four
(10.5%) of the patients.
Conclusion: AL combination therapy was fully effective for treatment of P. vivax malaria in the study in eastern
Sudan.
Trial registration: Trial. Gov: NCT01625871
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Plasmodium vivax infection is a major global health
problem. This species of parasite has the broadest geo-
graphic distribution of the five malaria species known to
infect humans [1]. There are about 2.5 billion people at
risk of malaria and an estimated 80 to 300 million clin-
ical cases of P. vivax annually [2,3]. Although P. vivax is
mainly endemic in Southeast Asia and Latin America [3], it
has recently been observed in Ethiopia and Sudan [4-8].
Malaria is a important health problem in Sudan, and
in 2002, an estimated 9 million disease episodes and
44,000 deaths from the disease occurred [9]. The spread
of multidrug-resistant Plasmodium falciparum malaria
in Sudan [10,11] has led to adoption of artemisinin-based* Correspondence: ishagadam@hotmail.com
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reproduction in any medium, provided the orcombination therapy (ACT), with artesunate–sulphadox-
ine–pyrimethamine (AS–SP) and artemether–lumefantrine
(AL) becoming the recommended first- and second-
line treatments for uncomplicated P. falciparum mal-
aria, respectively.
Early diagnosis and effective treatment with an appro-
priate drug is one of the main components of the World
Health Organization’s strategy to reduce malaria related
mortality [12]. Episodes of P. vivax infection should
prompt urgent treatment with effective anti-malarial
medication [13]. While most malaria endemic countries
have adopted ACT to reduce the risk of multidrug re-
sistant strains of P. falciparum occurring [10], chloro-
quine remains the first-line treatment for P. vivax in
most endemic countries. However, there is growing evi-
dence that the efficacy of chloroquine against P. vivax is de-
clining in many areas, especially Southeast Asia [14-16].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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P. falciparum is preferred, especially in a country like
Sudan where chloroquine is no longer registered or
available [17]. The far-reaching adoption of ACT as an
effective first-line therapy for P. falciparum has led to
a closer examination of their role in the management
of P. vivax malaria. AL is one such combination therapy
that is widely used to treat uncomplicated P. falciparum
malaria, and is the first-line treatment for P. vivax malaria
according to the national malaria control programme in
Sudan. However, there is no published data on the efficacy
of AL for the treatment of P. vivax malaria in Sudan.
Therefore, the efficacy of AL for the treatment of uncom-
plicated P. vivax malaria was investigated in Sudan. The
study was conducted at a health centre in eastern Sudan,
an area characterized by unstable malaria transmission [18].
Recently, however, the most severe form of P. vivax malar-
ial disease has been observed in the area [8]. The study is of
paramount importance because it aims to provide Sudanese
health care professionals and public health planners withFigure 1 Map of Sudan.the fundamental data necessary for developing an effective
programme for malaria control.Methods
This observational (without sample size calculation)
clinical trial was conducted at the Fatima Eldeaig Health
Centre in Kassala, eastern Sudan (located 600 km
from Khartoum, Sudan) and took place from October
to December 2011 (Figure 1). The World Health
Organization (WHO) guidelines for assessment of the
efficacy of anti-malarial drugs were adopted [19].
Febrile patients (axillary temperature ≥ 37.5°C) with
confirmed blood films for P. vivax mono-infection and
willing to participate in the study were enrolled. Those
individuals with severe malnutrition, pregnancy, or
with a history of allergy and/or intolerance to the
drugs were excluded. Informed consent was obtained
from all of the patients, or in the case of children, their
guardians. Structured questionnaires were used together
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(including the duration of the illness) and physical findings.
Thick and thin blood smears were prepared and
stained with 2% Giemsa solution for 30 minutes. Thick
blood films were used for counting parasite numbers
and for estimating parasite densities. Gametocytes were
counted against 200 leukocytes, and parasite densities
estimated using 8,000 white blood cells (WBCs)/μL of
blood as the multiplier. Smears were considered nega-
tives if no parasites could be seen in 100 high-power
microscopic fields. Blood films were double checked
(blind) by two independent examiners, and discordant
results were agreed on after evaluating the evidence of
each examiner. Parasite densities differing by more than
10% between the different microscopists were evaluated by
a third microscopist, whose result was deemed to be final.
Treatment
AL (CoartemW; Novartis, Basel, Switzerland) was admi-
nistered over a three-day period. AL tablets contained
20 mg of artemether and 120 mg of lumefantrine.
Patients were weighed and those corresponding to 5–14,
15–24, 25– 34 or >35 kg were each given six doses of
AL (at 0, 8, 24, 36, 48 and 60 h), each dose consisted of
one, two, three or four tablets, respectively. The morning
dose was given at the health Centre under the direct
supervision of a medical officer. Young children who
could not swallow tablets were given suspensions cre-
ated by crushing and dissolving their tablets in water.
All patients were observed for vomiting for 1 h after
each treatment. If vomiting occurred within 30 min of a
dose, a second full dose was administered. If vomiting
occurred 31–60 min after a dose, however, only half a
dose was given. If vomiting occurred after a repeated
(full or half ) dose, the patient was given a quinine infu-
sion and excluded from the study. These instructions
were given to all of the patients (or guardian in the case
of children) because the evening dose was given un-
supervised. Patients also received unsupervised prima-
quine tablets (15 mg) daily for 14 days.
Treatment outcomes
Patients were asked to return on days 1, 2, 3, 7, 14, 21
and 28 of the study, or at any other time if they felt un-
well. During each visit, the participants’ temperatures
were measured and blood smears were prepared and
checked as described above. Treatment outcomes were
classified according to WHO guidelines for evaluation of
the therapeutic efficacy of antimalarial drugs in the
treatment of uncomplicated malaria [19]. During follow-
up, the patients were asked if they had any adverse
effects that might have been expected from the treat-
ment itself (nausea, vomiting, abdominal pain, dizziness
and rash). These effects were considered to be AL-relatedif they had not been reported when the patient first pre-
sented for treatment at the Health Centre. The primary
outcome was the cure rate, which was defined as the
percentage of the patients completing follow-up that
had adequate clinical and parasitological responses
(ACPR) after 28 days. Secondary outcomes comprised
the frequencies of early treatment failure, late clinical
response, late parasitological response, and adverse
events, and the time taken to reduce fever and clear
parasitaemia. Early treatment failure was defined as the
development of danger signs or severe malaria, in the
presence of parasitaemia, on days 1, 2 and/or 3, a day-2
parasitaemia that was higher than the day-0, the pres-
ence of both fever and parasitaemia on day 3, and/or a
day-3 parasitaemia that was 20% of the day-0 value. A
late treatment failure was defined as the development
of danger signs or severe malaria, in the presence of
parasitaemia, after day 3, the presence of both fever
and parasitaemia on or after day 4, and/or the presence
of parasitaemia after day 7.
Data analysis
Data were entered into a computer database and analysed
using SPSS software (version 20, Chicago, IL, USA). Mean
and SD were calculated for the variables presented. The
intention-to-treat analysis included all enrolled patients
who met the inclusion criteria and took at least one full
dose of AL. Patients lost to follow-up or withdrawn from
the study were considered to be treatment failures. The
per protocol (PP) analysis of outcomes included data for
patients who had completed the follow-up. Those patients
lost to the follow-up or were withdrawn because of proto-
col violations were excluded from the PP analysis.
Ethics
The current study received ethical approval from the
Health Research Board at the Ministry of Health in
Kassala state, eastern Sudan. The trial was registered at
Trial. Gov: NCT01625871.
Results
During the study period, 1,185 febrile patients presented
to the health centre, of which 251 had uncomplicated
diagnoses of malaria confirmed. Out of these 251 patients,
204, 43, and four were uncomplicated P. falciparum, un-
complicated P. vivax and mixed P. falciparum and P.
vivax infections, respectively (Figure 2). Therefore, the P.
falciparum: P. vivax ratio was 4.7:1. Of the 43 enrolled
patients with uncomplicated P. vivax malaria, 38 (88.37%)
completed the 28 days follow-up, but the remaining 5
were lost to follow- up. The base line characteristics of the
study participants are shown in Table 1. The range of the
age, weight and parasitaemia was 4–60 years, 13–95 kg
years, and 200–8,480.0 rings/μl, respectively. The majority
Febrile patients presented to the health center (n= 1185)
Completed the 28 days of follow-up (n=38)
Patients who had confirmed uncomplicated malaria (n=251)
Mixed P. falciparum and P. vivax malaria (n=4)
Had adequate clinical and parasitological response (n=38)
Lost to follow-up (n=5)
P. vivax malaria (n =43)P. falciparum malaria (n=204)
Figure 2 Patient enrollment and follow-up during the study.
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was aged less than five years (a 4-year old). Excluding
those with gametocytes on day 0 (two patients), no new
carriers were identified during the 28-day follow-up. All
of the day 0 slides that were submitted to the National
Laboratory at the National Malaria Control Programme
for quality control were identified as containing the
same species of malaria parasite (i.e., P. vivax).
On day 1 all patients were afebrile, but 2 (5.3%) of
them were parasitaemic. By day 3, all patients were
afebrile and aparasitaemic. All of the patients 38 (100%)
responded to treatment with AL and had ACPR. The
cure rate was 100% and 88.4% for the per protocol ana-
lysis and for the intention to treat analysis, respectively.
Mild adverse effects (nausea, vomiting, abdominal pain,
dizziness and/or rash) that resolved spontaneously were
observed in four (10.5%) patients.Table 1 Baseline characteristics of patients treated with
artemether-lumefantrine in eastern Sudan
Variable Mean (SD)
Age in years 25.1 (1.5)
Weight in kg 50.2 (2.5)
Temperature °C 38.5 (0.6)
Duration of the illness in days prior to diagnosis 4.1 ( 2.4)
Geometric mean of asexual-stage parasitaemia per μL 3272.0 (2029.3)Discussion
The current study showed full efficacy (per protocol
analyses) of the AL combination for treatment of
P. vivax in eastern Sudan. Consistent with a recent
study, the present study showed that P. vivax is a health
problem and that its ratio to P. falciparum has increased
[8]. Previous studies showed that AL had a high efficacy
(98.7%) for treatment of uncomplicated P. falciparum
malaria in eastern Sudan as well as other regions of the
country [20,21]. Interestingly, in neighbouring Ethiopia,
a higher failure rate was observed (19%) when AL was
compared with chloroquine for treatment of uncompli-
cated P. vivax malaria [4]. The high AL failure rate in
Ethiopia was attributed to the need for patients to take the
evening dose of the drug unsupervised [4]. In this context,
it is noteworthy that the emergence of chloroquine-
resistant P. vivax was first confirmed in Ethiopia [22]. The
full efficacy of AL for the treatment of P. vivax malaria in
the present study is consistent with other studies that
showed a rapid clearance of P. vivax parasitaemia and
fever and an overall high cure rate for AL treatment of
P. vivax malaria [13,23].
Chloroquine remains the drug of choice for treating
P. vivax infection according to WHO guidelines and it is
still effective in most malaria endemic areas [24,25]. Un-
fortunately, substantial levels of chloroquine-resistant
P. vivax parasites have been observed in South East Asia
[26-28]. In addition, some studies have reported
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Africa [4,22,29]. Therefore, the idea of using a single
first-line therapy that is effective against both P. vivax
and P. falciparum is attractive, especially in settings
where two malaria parasite species are co-endemic. ACT
is highly effective against uncomplicated P. falciparum
malaria and, as a consequence of high levels of chloro-
quine resistance, is now widely adopted as the first-line
therapy in most malaria endemic countries, including
Sudan [10]. Indeed, some countries such as Papua New
Guinea and Indonesia have adopted ACT as the first-line
therapy for P. vivax and P. falciparum malaria [16]. A
policy whereby use of a unified first-line therapy based
on ACT was implemented could have great public
health value in that it would simplify treatment, manage-
ment and logistics of malaria disease control. It should
be mentioned that chloroquine is no longer registered or
available for use in Sudan, so as to avoid the problem of
P. falciparum infection being treated with chloroquine.
The limitations of this study concern its non-
randomized character and small sample size; however,
with a lack of published data about the efficacy of AL
against P. vivax malaria, this study provides useful
insight into AL treatment of P. vivax infection. Secondly,
the 28-day follow-up of patients treated with AL is an-
other limitation; a longer follow-up period could be ad-
vantageous as it would provide more information about
AL treatment outcomes. Thirdly, in this study, patients
were treated with primaquine without prior assessment
of their G6PD enzyme levels, because G6PD enzyme
tests were not available.
Conclusion
Although this study did not detect any treatment failures
during treatment of uncomplicated P. vivax malaria
using AL in this area of Sudan.
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